Загрузка...
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, with or without BCL2 translocations, have been associated with inferior survival in DLBCL. We investigated...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Clinical Oncology
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3454768/ https://ncbi.nlm.nih.gov/pubmed/22851565 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.41.0985 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|